Residential Recovery for Seniors Act

Full-Year Continuing Appropriations and Extensions Act, 2025 (H.R. 1968); Residential Recovery for Seniors Act (H.R.9232).

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Full-Year Continuing Appropriations and Extensions Act, 2025 (H.R. 1968); Residential Recovery for Seniors Act (H.R.9232).

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

SUPPORT for Patients and Communities Reauthorization Act of 2025 (H.R. 2783); Ensuring Excellence in Mental Health Act (S.3402); Community Mental Wellness Worker Training Act (H.R.5733); 9-8-8 CONNECT Act (H.R. 8122); Residential Recovery for Seniors Act (H.R.9232).

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

SUPPORT for Patients and Communities Reauthorization Act of 2025 (H.R. 2783); Ensuring Excellence in Mental Health Act (S.3402); Community Mental Wellness Worker Training Act (H.R.5733); 9-8-8 CONNECT Act (H.R. 8122); Residential Recovery for Seniors Act (H.R.9232).

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Full-Year Continuing Appropriations and Extensions Act, 2025 (H.R. 1968); Residential Recovery for Seniors Act (H.R.9232).

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Full-Year Continuing Appropriations and Extensions Act, 2025 (H.R. 1968); Residential Recovery for Seniors Act (H.R.9232).

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Seeking Medicare reimbursement for residential treatment services. Residential Recovery for Seniors Act (S. 4860/HR 9232)

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Seeking Medicare reimbursement Seeking Medicare reimbursement for residential treatment services. Residential Recovery for Seniors Act (S. 4860/HR 9232)

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Growing the mental and behavioral health workforce. Improving mental health and substance use services via Certified Community Behavioral Health Clinics. 9-8-8 Implementation Act of 2023, H.R. 4851. Ensuring Excellence in Mental Health Act, S. 2993. SUPPORT for Patients and Communities Reauthorization Act, H.R. 4531/S. 2433. Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024, S.2624/ House Version. Better Mental Health Care, Lower-Cost Drugs, and Extenders Act. Consolidated Appropriations Act, 2024, P.L. 118-42. Further Consolidated Appropriations Act, 2024, P.L. 118-47. Community Mental Wellness Worker Training Act, H.R. 8680. Residential Recovery for Seniors Act (S. 4860/HR 9232). Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 (S. 4942/HR 9029).

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Growing the mental and behavioral health workforce. Improving mental health and substance use services via Certified Community Behavioral Health Clinics. 9-8-8 Implementation Act of 2023, H.R. 4851. Ensuring Excellence in Mental Health Act, S. 2993. SUPPORT for Patients and Communities Reauthorization Act, H.R. 4531/S. 2433. Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024, S.2624/ House Version. Better Mental Health Care, Lower-Cost Drugs, and Extenders Act. Consolidated Appropriations Act, 2024, P.L. 118-42. Further Consolidated Appropriations Act, 2024, P.L. 118-47. Community Mental Wellness Worker Training Act, H.R. 8680; Residential Recovery for Seniors Act (S. 4860/HR 9232). Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 (S. 4942/HR 9029).

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Medicare reimbursement for addiction counselors Medicare coverage for substance use disorder treatment services Consolidated Appropriations Act, 2023 implementation (S.923) Better Mental Health Care for Americans Act (H.R.2400/S.1165) Reentry Act (H.R. 1638/S. 838) Improving Access to Mental Health Act (S.3921/H.R. 4892) Medicaid Bump Act (H.R.6928) CONNECT Act of 2024 Gaps in substance use disorder services Issues surrounding peer support services (H.R. 6748/S. 3498) PEERS in Medicare Act Issues surrounding Medicare Part B (H.R. 9232/S. 4860) Residential Recovery for Seniors MHPAEA Application to Medicare (H.R.2400/S.1165) Reentry Act of 2023 (H.R.3074/S.971) Due Process Continuity of Care Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Ensuring Excellence in Mental Health Act (CCBHC 2.0) (S. 2993/H.R. 8543), all provisions related to expansion grant funding for CCBHCs, childrens clinic grant funding, and CCBHC certification processes. Mental Health Access Improvement Act (S. 828/H.R. 432), all provisions related to allowing marriage and family therapists and mental health counselors to directly bill Medicare for their services. Medicaid Reentry Act (H.R. 2400/S. 1165), all provisions related to allowing Medicaid coverage for eligible incarcerated individuals to be re-established up to 30 days before their release from jail or prison. Due Process Continuity of Care Act (H.R. 3074/S. 971), all provisions related to the removal of the Medicaid coverage exclusion for inmates in custody pending disposition of charges. ADAPT Act (S.2511), all provisions related to allowing certain supervised psychology trainees to provide mental health services and bill Medicare, Medicaid and CHIP. PEERS in Medicare Act (H.R. 6748/S. 3498), all provisions related to creating a definition of peers in the Medicare program and making peer services reimbursable through Medicare in certain community-based settings. Residential Recovery for Seniors Act (S. 4860/H.R. 9232), all provisions related to establishing Medicare coverage for residential addiction treatment programs meeting nationally recognized standards. Language to expand NHSC allowable use of hours of service delivered outside clinic walls, all provisions related to expanding allowable use for hours of service.

Client expense: $112,806 · Firm income: Not reported

Ensuring Excellence in Mental Health Act (CCBHC 2.0) (S. 2993/H.R. 8543), all provisions related to expansion grant funding for CCBHCs, childrens clinic grant funding, and CCBHC certification processes. Mental Health Access Improvement Act (S. 828/H.R. 432), all provisions related to allowing marriage and family therapists and mental health counselors to directly bill Medicare for their services. Medicaid Reentry Act (H.R. 2400/S. 1165), all provisions related to allowing Medicaid coverage for eligible incarcerated individuals to be re-established up to 30 days before their release from jail or prison. Due Process Continuity of Care Act (H.R. 3074/S. 971), all provisions related to the removal of the Medicaid coverage exclusion for inmates in custody pending disposition of charges. ADAPT Act (S.2511), all provisions related to allowing certain supervised psychology trainees to provide mental health services and bill Medicare, Medicaid and CHIP. PEERS in Medicare Act (H.R. 6748/S. 3498), all provisions related to creating a definition of peers in the Medicare program and making peer services reimbursable through Medicare in certain community-based settings. Residential Recovery for Seniors Act (S. 4860/H.R. 9232), all provisions related to establishing Medicare coverage for residential addiction treatment programs meeting nationally recognized standards. Language to expand NHSC allowable use of hours of service delivered outside clinic walls, all provisions related to expanding allowable use for hours of service.

Client expense: $154,891 · Firm income: Not reported

Medicare reimbursement for addiction counselors Medicare coverage for substance use disorder treatment services Consolidated Appropriations Act, 2023 implementation (S.923) Better Mental Health Care for Americans Act (H.R.2400/S.1165) Reentry Act (H.R. 1638/S. 838) Improving Access to Mental Health Act (S.3921/H.R. 4892) Medicaid Bump Act (H.R.6928) CONNECT Act of 2024 Gaps in substance use disorder services Issues surrounding peer support services (H.R. 6748/S. 3498) PEERS in Medicare Act Issues surrounding Medicare Part B (H.R. 9232/S. 4860) Residential Recovery for Seniors

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Seeking Medicare reimbursement for residential treatment services. Residential Recovery for Seniors Act (S. 4860/HR 9232)

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Seeking Medicare reimbursement Seeking Medicare reimbursement for residential treatment services. Residential Recovery for Seniors Act (S. 4860/HR 9232)

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Growing the mental and behavioral health workforce. Improving mental health and substance use services via Certified Community Behavioral Health Clinics. 9-8-8 Implementation Act of 2023, H.R. 4851. Ensuring Excellence in Mental Health Act, S. 2993. SUPPORT for Patients and Communities Reauthorization Act, H.R. 4531/S. 2433. Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024, S.2624/ House Version. Better Mental Health Care, Lower-Cost Drugs, and Extenders Act. Consolidated Appropriations Act, 2024, P.L. 118-42. Further Consolidated Appropriations Act, 2024, P.L. 118-47. Community Mental Wellness Worker Training Act, H.R. 8680. Residential Recovery for Seniors Act (S. 4860/HR 9232). Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 (S. 4942/HR 9029).

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Growing the mental and behavioral health workforce. Improving mental health and substance use services via Certified Community Behavioral Health Clinics. 9-8-8 Implementation Act of 2023, H.R. 4851. Ensuring Excellence in Mental Health Act, S. 2993. SUPPORT for Patients and Communities Reauthorization Act, H.R. 4531/S. 2433. Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024, S.2624/ House Version. Better Mental Health Care, Lower-Cost Drugs, and Extenders Act. Consolidated Appropriations Act, 2024, P.L. 118-42. Further Consolidated Appropriations Act, 2024, P.L. 118-47. Community Mental Wellness Worker Training Act, H.R. 8680; Residential Recovery for Seniors Act (S. 4860/HR 9232). Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 (S. 4942/HR 9029).

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.